Zevra Therapeutics Stock Price To Book
| ZVRA Stock | 9.50 0.07 0.74% |
Zevra Therapeutics fundamentals help investors to digest information that contributes to Zevra Therapeutics' financial success or failures. It also enables traders to predict the movement of Zevra Stock. The fundamental analysis module provides a way to measure Zevra Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zevra Therapeutics stock.
The current year's Price To Book Ratio is expected to grow to 3.94. Zevra | Price To Book |
Zevra Therapeutics Company Price To Book Analysis
Zevra Therapeutics' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Zevra Therapeutics Price To Book | 7.27 X |
Most of Zevra Therapeutics' fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zevra Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Zevra Price To Book Driver Correlations
Understanding the fundamental principles of building solid financial models for Zevra Therapeutics is extremely important. It helps to project a fair market value of Zevra Stock properly, considering its historical fundamentals such as Price To Book. Since Zevra Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Zevra Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Zevra Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Zevra Book Value Per Share
Book Value Per Share |
|
Based on the latest financial disclosure, Zevra Therapeutics has a Price To Book of 7.2678 times. This is 71.7% lower than that of the Biotechnology sector and 20.33% higher than that of the Health Care industry. The price to book for all United States stocks is 23.58% higher than that of the company.
Zevra Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zevra Therapeutics' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Zevra Therapeutics could also be used in its relative valuation, which is a method of valuing Zevra Therapeutics by comparing valuation metrics of similar companies.Zevra Therapeutics is currently under evaluation in price to book category among its peers.
Zevra Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Zevra Therapeutics from analyzing Zevra Therapeutics' financial statements. These drivers represent accounts that assess Zevra Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Zevra Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 60.8M | 31.9M | 11.2M | 259.3M | 233.3M | 245.0M | |
| Enterprise Value | 143.4M | 95.6M | 87.6M | 148.5M | 133.7M | 87.9M |
Zevra Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Zevra Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Zevra Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Zevra Fundamentals
| Return On Equity | -1.31 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | (7.39) % | ||||
| Current Valuation | 477.62 M | ||||
| Shares Outstanding | 53.38 M | ||||
| Shares Owned By Insiders | 6.61 % | ||||
| Shares Owned By Institutions | 54.46 % | ||||
| Number Of Shares Shorted | 4.11 M | ||||
| Price To Book | 7.27 X | ||||
| Price To Sales | 20.71 X | ||||
| Revenue | 27.46 M | ||||
| Gross Profit | 10.12 M | ||||
| EBITDA | (48.6 M) | ||||
| Net Income | (46.05 M) | ||||
| Total Debt | 43.77 M | ||||
| Book Value Per Share | 1.31 X | ||||
| Cash Flow From Operations | (33.53 M) | ||||
| Short Ratio | 6.66 X | ||||
| Earnings Per Share | (2.13) X | ||||
| Price To Earnings To Growth | 10.67 X | ||||
| Target Price | 20.0 | ||||
| Number Of Employees | 65 | ||||
| Beta | 1.93 | ||||
| Market Capitalization | 507.07 M | ||||
| Total Asset | 172.33 M | ||||
| Retained Earnings | (399.78 M) | ||||
| Working Capital | 81.3 M | ||||
| Net Asset | 172.33 M |
About Zevra Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zevra Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zevra Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zevra Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zevra Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zevra Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zevra Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zevra Therapeutics Stock:Check out Zevra Therapeutics Piotroski F Score and Zevra Therapeutics Altman Z Score analysis. For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zevra Therapeutics. If investors know Zevra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zevra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.13) | Revenue Per Share 0.575 | Quarterly Revenue Growth 0.276 | Return On Assets (0.33) | Return On Equity (1.31) |
The market value of Zevra Therapeutics is measured differently than its book value, which is the value of Zevra that is recorded on the company's balance sheet. Investors also form their own opinion of Zevra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Zevra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zevra Therapeutics' market value can be influenced by many factors that don't directly affect Zevra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zevra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zevra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zevra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.